Last reviewed · How we verify
Gaba (aminobutyric acid)
At a glance
| Generic name | aminobutyric acid |
|---|---|
| Drug class | alpha-Adrenergic Agonist [EPC] |
| Target | Platelet glycoprotein VI, Sodium- and chloride-dependent GABA transporter 3, Gamma-aminobutyric acid receptor subunit rho-1 |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
- Somnolence
- Dizziness
- Ataxia
- Fatigue
- Nystagmus
- Tremor
- Peripheral edema
- Dyspepsia
- Dry mouth or throat
- Constipation
- Dysarthria
- Back pain
Serious adverse events
- Emotional lability
- Hyperkinesia
Key clinical trials
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- Effectiveness of a Bilayering Serum and Cream Containing GABA, DMAE, Cysteamine, and Bakuchiol for Skin Whitening and Anti-Aging (PHASE2)
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2,PHASE3)
- Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy (PHASE2)
- Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver (PHASE4)
- Plant Protein With Ashwagandha-Rhodiola for Sleep Quality (NA)
- Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain (PHASE4)
- Baclofen for Children With Rumination Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gaba CI brief — competitive landscape report
- Gaba updates RSS · CI watch RSS
- portfolio CI